If you or a loved one is taking Tysabri, you may be concerned about the risk of progressive multifocal leukoencephalopathy (PML). This rare but serious brain infection is a known complication of the medication. Building on decades of post-marketing surveillance and clinical research, this page provides clear, factual information about PML risk factors, early symptoms, and the importance of regular monitoring.
Building on the need for targeted risk communication, this section bridges to the specific case of Tysabri (natalizumab) and its association with progressive multifocal leukoencephalopathy (PML). Tysabri is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn's disease. Its use carries a well-documented risk of PML, a severe opportunistic brain infection caused by the JC virus. The following narrative synthesizes evidence from FDA-approved labeling and clinical trial data to describe the medical and risk landscape surrounding Tysabri-associated PML, including settlement-related considerations for affected patients.
PML is an opportunistic viral infection of the brain caused by the JC virus, typically occurring only in immunocompromised individuals. The condition usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Clinical presentation often includes progressive neurological deficits such as weakness, cognitive decline, visual disturbances, and coordination problems. Diagnosis relies on brain imaging, typically MRI showing characteristic white matter lesions, and detection of JC virus DNA in cerebrospinal fluid. Early recognition is critical because prompt intervention may improve outcomes, though prognosis remains poor.
Tysabri is a monoclonal antibody that binds to alpha-4 integrin, preventing immune cell migration into the central nervous system. This mechanism reduces inflammation in multiple sclerosis but also impairs immune surveillance against JC virus, creating a permissive environment for PML development. In clinical trials, PML occurred in three patients who received Tysabri (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Two cases were observed among 1869 multiple sclerosis patients treated for a median of 120 weeks; these patients had also received interferon beta-1a. The third case occurred after eight doses in one of 1043 Crohn's disease patients evaluated for PML (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Other common adverse reactions include headache, influenza-like illness, peripheral edema, toothache, infections (sinusitis, vaginal infections, viral infection), respiratory symptoms (cough), and musculoskeletal pain (back pain) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
The primary mechanism involves Tysabri's inhibition of lymphocyte trafficking across the blood-brain barrier. By blocking alpha-4 integrin, the drug reduces immune surveillance in the central nervous system, allowing latent JC virus to reactivate and cause lytic infection of oligodendrocytes. Three established risk factors for PML in Tysabri-treated patients include: presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating and continuing therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
The FDA-approved labeling includes a boxed warning stating that Tysabri increases the risk of PML, an opportunistic viral infection of the brain that usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The warning specifies risk factors (anti-JCV antibodies, duration of therapy, prior immunosuppressant use) and instructs healthcare professionals to monitor patients for any new sign or symptom suggestive of PML and to withhold Tysabri immediately at the first sign or symptom (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Because of the PML risk, Tysabri is available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these warnings, some patients have developed PML, raising questions about whether the warnings were sufficient to allow informed decision-making.
Patients who develop PML after Tysabri therapy may pursue legal claims alleging inadequate warning of the risk. Settlement criteria typically consider the presence of anti-JCV antibodies, duration of Tysabri use, prior immunosuppressant exposure, and the timing of symptom onset relative to treatment. The boxed warning explicitly states that Tysabri increases PML risk and that risk factors include anti-JCV antibodies, longer treatment duration, and prior immunosuppressant use (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). For settlement purposes, documentation of these risk factors and the patient's awareness of them is often central. Additionally, the timeline between exposure and documented harm is critical; PML typically occurs after prolonged treatment, with clinical trial data showing cases after a median of 120 weeks in multiple sclerosis patients and after eight doses in a Crohn's disease patient (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Patients who developed PML within the expected risk window may have stronger claims.
The latency between Tysabri initiation and PML diagnosis varies. In clinical trials, two multiple sclerosis patients developed PML after a median of 120 weeks of treatment, and one Crohn's disease patient developed PML after eight doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The labeling notes that longer treatment duration, especially beyond two years, increases risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). This timeline is relevant for both clinical monitoring and legal claims, as it establishes a temporal relationship between drug exposure and harm.
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Tysabri (natalizumab) is a biologic therapy for multiple sclerosis and Crohn's disease. It increases the risk of progressive multifocal leukoencephalopathy (PML), a severe brain infection caused by the JC virus, due to its mechanism of reducing immune surveillance in the central nervous system (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
Settlement criteria typically include presence of anti-JCV antibodies, duration of Tysabri use (especially beyond two years), prior immunosuppressant exposure, and timing of symptom onset relative to treatment. Documentation of these risk factors and patient awareness is often central (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
In clinical trials, PML occurred after a median of 120 weeks in multiple sclerosis patients and after eight doses in a Crohn's disease patient. Longer treatment duration, especially beyond two years, increases risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962).
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.
Individuals with documented Tysabri exposure and a related diagnosis may request an independent, no-cost eligibility review.